Preeclampsia and Pregnancy-Related Hypertensive Disorders

Hypertension

Volumn 67, Issue 2, 2016, Pages 238-242

  Karumanchi, S Ananth ^a   Granger, Joey P ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; BIOLOGICAL MARKER; COPEPTIN; CYSTATIN C; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PLACENTAL GROWTH FACTOR; PRAVASTATIN; PREPROENDOTHELIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; VASCULOTROPIN RECEPTOR 1; VASOPRESSIN;

ARTICLE; ASTROCYTOSIS; BLOOD VESSEL REACTIVITY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; GLOMERULOPATHY; HUMAN; HYPERCHOLESTEROLEMIA; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PREDICTION; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; SCREENING; BLOOD; BLOOD PRESSURE; EARLY DIAGNOSIS; FEMALE; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY COMPLICATION;

BIOMARKERS; BLOOD PRESSURE; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTENSION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 84954362406     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05024     Document Type: Article

References (53)

1. Amaral LM, Cornelius DC, Harmon A, Moseley J, Martin JN Jr, LaMarca B. 17-Hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model. Hypertension. 2015;65:225-231. doi: 10.1161/HYPERTENSIONAHA.114.04484.
2. Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, Hastie R, Onda K, Kaitu'u-Lino TJ. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66:687-697; discussion 445. doi: 10.1161/HYPERTENSIONAHA.115.05445.
3. Burwick RM, Easter SR, Dawood HY, Yamamoto HS, Fichorova RN, Feinberg BB. Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia. Hypertension. 2014;64:833-838. doi: 10.1161/HYPERTENSIONAHA.114.03456.
4. Chen M, Dasgupta C, Xiong F, Zhang L. Epigenetic upregulation of largeconductance Ca2+-activated K+ channel expression in uterine vascular adaptation to pregnancy. Hypertension. 2014;64:610-618. doi: 10.1161/HYPERTENSIONAHA.114.03407.
5. Cornelius DC. Copeptin: a new biomarker that is specific for preeclampsia Hypertension. 2014;64:1189-1191. doi: 10.1161/HYPERTENSIONAHA.114.04255.
6. Elliott SE, Parchim NF, Liu C, Xia Y, Kellems RE, Soffici AR, Daugherty PS. Characterization of antibody specificities associated with preeclampsia. Hypertension. 2014;63:1086-1093. doi: 10.1161/HYPERTENSIONAHA.113.02362.
7. Huda SS, Forrest R, Paterson N, Jordan F, Sattar N, Freeman DJ. In preeclampsia, maternal third trimester subcutaneous adipocyte lipolysis is more resistant to suppression by insulin than in healthy pregnancy. Hypertension. 2014;63:1094-1101. doi: 10.1161/HYPERTENSIONAHA.113.01824.
8. Iriyama T, Wang W, Parchim NF, Song A, Blackwell SC, Sibai BM, Kellems RE, Xia Y. Hypoxia-independent upregulation of placental hypoxia inducible factor-1 gene expression contributes to the pathogenesis of preeclampsia. Hypertension. 2015;65:1307-1315. doi: 10.1161/HYPERTENSIONAHA.115.05314.
9. Janzarik WG, Ehlers E, Ehmann R, Gerds TA, Schork J, Mayer S, Gabriel B, Weiller C, Prömpeler H, Reinhard M. Dynamic cerebral autoregulation in pregnancy and the risk of preeclampsia. Hypertension. 2014;63:161-166. doi: 10.1161/HYPERTENSIONAHA.113.01667.
10. Kaartokallio T, Klemetti MM, Timonen A, Uotila J, Heinonen S, Kajantie E, Kere J, Kivinen K, Pouta A, Lakkisto P, Laivuori H. Microsatellite polymorphism in the heme oxygenase-1 promoter is associated with nonsevere and late-onset preeclampsia. Hypertension. 2014;64:172-177. doi: 10.1161/HYPERTENSIONAHA.114.03337.
11. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, McCowan LM, Simpson NA, Dekker GA, Roberts CT, Rodems K, Noland B, Raymundo M, Walker JJ, North RA. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension. 2014;64:644-652. doi: 10.1161/HYPERTENSIONAHA.114.03578.
12. Linzke N, Schumacher A, Woidacki K, Croy BA, Zenclussen AC. Carbon monoxide promotes proliferation of uterine natural killer cells and remodeling of spiral arteries in pregnant hypertensive heme oxygenase-1 mutant mice. Hypertension. 2014;63:580-588. doi: 10.1161/HYPERTENSIONAHA.113.02403.
13. Liu C, Wang W, Parchim N, Irani RA, Blackwell SC, Sibai B, Jin J, Kellems RE, Xia Y. Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification. Hypertension. 2014;63:353-361. doi: 10.1161/HYPERTENSIONAHA.113.02361.
14. Luo R, Shao X, Xu P, Liu Y, Wang Y, Zhao Y, Liu M, Ji L, Li YX, Chang C, Qiao J, Peng C, Wang YL. MicroRNA-210 contributes to preeclampsia by downregulating potassium channel modulatory factor 1. Hypertension. 2014;64:839-845. doi: 10.1161/HYPERTENSIONAHA.114.03530.
15. Mazzuca MQ, Li W, Reslan OM, Yu P, Mata KM, Khalil RA. Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension. 2014;64:632-643. doi: 10.1161/HYPERTENSIONAHA.114.03315.
16. Munõz-Hernandez R, Miranda ML, Stiefel P, Lin RZ, Praena-Fernández JM, Dominguez-Simeon MJ, Villar J, Moreno-Luna R, Melero-Martin JM. Decreased level of cord blood circulating endothelial colony-forming cells in preeclampsia. Hypertension. 2014;64:165-171. doi: 10.1161/HYPERTENSIONAHA.113.03058.
17. Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, Poston L, Roberts JM; Global Pregnancy CoLaboratory. Strategy for standardization of preeclampsia research study design. Hypertension. 2014;63:1293-1301. doi: 10.1161/HYPERTENSIONAHA.113.02664.
18. Nayeri UA, Buhimschi IA, Laky CA, Cross SN, Duzyj CM, Ramma W, Sibai BM, Funai EF, Ahmed A, Buhimschi CS. Antenatal corticosteroids impact the inflammatory rather than the antiangiogenic profile of women with preeclampsia. Hypertension. 2014;63:1285-1292. doi: 10.1161/HYPERTENSIONAHA.114.03173.
19. Onda K, Tong S, Nakahara A, Kondo M, Monchusho H, Hirano T, Kaitu'u-Lino T, Beard S, Binder N, Tuohey L, Brownfoot F, Hannan NJ. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia. Hypertension. 2015;65:855-862. doi: 10.1161/HYPERTENSIONAHA.114.04781.
20. Palmer KR, Kaitu'u-Lino TJ, Hastie R, Hannan NJ, Ye L, Binder N, Cannon P, Tuohey L, Johns TG, Shub A, Tong S. Placentalspecific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity. Hypertension. 2015;66:1251-1259. doi: 10.1161/HYPERTENSIONAHA.115.05883.
21. Parchim NF, Wang W, Iriyama T, Ashimi OA, Siddiqui AH, Blackwell S, Sibai B, Kellems RE, Xia Y. Neurokinin 3 receptor and phosphocholine transferase: missing factors for pathogenesis of C-reactive protein in preeclampsia. Hypertension. 2015;65:430-439. doi: 10.1161/HYPERTENSIONAHA.114.04439.
22. Pedersen M, Stayner L, Slama R, Sørensen M, Figueras F, Nieuwenhuijsen MJ, Raaschou-Nielsen O, Dadvand P. Ambient air pollution and pregnancy-induced hypertensive disorders: a systematic review and meta-analysis. Hypertension. 2014;64:494-500. doi: 10.1161/HYPERTENSIONAHA.114.03545.
23. Penning M, Chua JS, van Kooten C, Zandbergen M, Buurma A, Schutte J, Bruijn JA, Khankin EV, Bloemenkamp K, Karumanchi SA, Baelde H. Classical complement pathway activation in the kidneys of women with preeclampsia. Hypertension. 2015;66:117-125. doi: 10.1161/HYPERTENSIONAHA.115.05484.
24. Pruthi D, Khankin EV, Blanton RM, Aronovitz M, Burke SD, McCurley A, Karumanchi SA, Jaffe IZ. Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. Hypertension. 2015;65:863-870. doi: 10.1161/HYPERTENSIONAHA.114.04971.
25. Przybyl L, Ibrahim T, Haase N, et al. Regulatory T cells ameliorate intrauterine growth retardation in a transgenic rat model for preeclampsia. Hypertension. 2015;65:1298-1306. doi: 10.1161/HYPERTENSIONAHA.114.04892.
26. Pulgar VM, Yamaleyeva LM, Varagic J, McGee CM, Bader M, Dechend R, Howlett AC, Brosnihan KB. Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis. Hypertension. 2014;64:619-625. doi: 10.1161/HYPERTENSIONAHA.114.03633.
27. Rabaglino MB, Post Uiterweer ED, Jeyabalan A, Hogge WA, Conrad KP. Bioinformatics approach reveals evidence for impaired endometrial maturation before and during early pregnancy in women who developed preeclampsia. Hypertension. 2015;65:421-429. doi: 10.1161/HYPERTENSIONAHA.114.04481.
28. Santillan MK, Santillan DA, Scroggins SM, Min JY, Sandgren JA, Pearson NA, Leslie KK, Hunter SK, Zamba GK, Gibson-Corley KN, Grobe JL. Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension. 2014;64:852-859. doi: 10.1161/HYPERTENSIONAHA.114.03848.
29. Taylor BD, Ness RB, Olsen J, Hougaard DM, Skogstrand K, Roberts JM, Haggerty CL. Serum leptin measured in early pregnancy is higher in women with preeclampsia compared with normotensive pregnant women. Hypertension. 2015;65:594-599. doi: 10.1161/HYPERTENSIONAHA.114.03979.
30. Veerbeek JH, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, Franx A, de Groot CJ, Koster MP. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancyinduced hypertension. Hypertension. 2015;65:600-606. doi: 10.1161/HYPERTENSIONAHA.114.04850.
31. Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM, Friesema EC, Russcher H, van den Meiracker AH, Visser W, Danser AH. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015;65:1316-1323. doi: 10.1161/HYPERTENSIONAHA.115.05267.
32. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346-352. doi: 10.1161/HYPERTENSIONAHA.113.01787.
33. Wallace K, Cornelius DC, Scott J, Heath J, Moseley J, Chatman K, LaMarca B. CD4+ T cells are important mediators of oxidative stress that cause hypertension in response to placental ischemia. Hypertension. 2014;64:1151-1158. doi: 10.1161/HYPERTENSIONAHA.114.03590.
34. Wang T, Zhou R, Gao L, Wang Y, Song C, Gong Y, Jia J, Xiong W, Dai L, Zhang L, Hu H. Elevation of urinary adipsin in preeclampsia: correlation with urine protein concentration and the potential use for a rapid diagnostic test. Hypertension. 2014;64:846-851. doi: 10.1161/HYPERTENSIONAHA.113.02688.
35. Wang W, Parchim NF, Iriyama T, et al. Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension. 2014;63:595-606. doi: 10.1161/HYPERTENSIONAHA.113.02458.
36. Xu P, Zhao Y, Liu M, Wang Y, Wang H, Li YX, Zhu X, Yao Y, Wang H, Qiao J, Ji L, Wang YL. Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. Hypertension. 2014;63:1276-1284. doi: 10.1161/HYPERTENSIONAHA.113.02647.
37. Yeung EH, Liu A, Mills JL, Zhang C, Männistö T, Lu Z, Tsai MY, Mendola P. Increased levels of copeptin before clinical diagnosis of preelcampsia. Hypertension. 2014;64:1362-1367. doi: 10.1161/HYPERTENSIONAHA.114.03762.
38. Zhu R, Huang X, Hu XQ, Xiao D, Zhang L. Gestational hypoxia increases reactive oxygen species and inhibits steroid hormonemediated upregulation of Ca(2+)-activated K(+) channel function in uterine arteries. Hypertension. 2014;64:415-422. doi: 10.1161/HYPERTENSIONAHA.114.03555.
39. O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation [published online ahead of print August 19, 2015]. Am J Obstet Gynecol. http://www.ajog.org/article/S0002-9378%2815%2900900-X/abstractcc=y=. doi: 10.1016/jajog.2015.08.034. Accessed December 15, 2015.
40. Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome [published online ahead of print July 29, 2015]. Ultrasound Obstet Gynecol. doi: 10.1002/uog.15663. http://onlinelibrary. wiley.com/doi/10.1002/uog.15663/abstract. Accessed December 15, 2015.
41. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119. doi: 10.1373/clinchem.2005.060038.
42. Sandgren JA, Scroggins SM, Santillan DA, Devor EJ, Gibson-Corley KN, Pierce GL, Sigmund CD, Santillan MK, Grobe JL. Vasopressin: the missing link for preeclampsia Am J Physiol Regul Integr Comp Physiol. 2015;309:R1062-R1064. doi: 10.1152/ajpregu.00073.2015.
43. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA. 2011;108:1451-1455. doi: 10.1073/pnas.1011293108.
44. Saad AF, Kechichian T, Yin H, Sbrana E, Longo M, Wen M, Tamayo E, Hankins GD, Saade GR, Costantine MM. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci. 2014;21:138-145. doi: 10.1177/1933719113492207.
45. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res. 2011;127(suppl 3):S72-S75. doi: 10.1016/S0049-3848(11)70020-2.
46. Cleary KL, Roney K, Costantine M. Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol. 2014;38:523-527. doi: 10.1053/j.semperi.2014.08.019.
47. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001;323:1213-1217.
48. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166-171. doi: 10.1161/HYPERTENSIONAHA.110.150078.
49. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366:1797-1803. doi: 10.1016/S0140-6736(05)67726-4.
50. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists' task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122-1131.
51. George EM, Granger JP. Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension. 2012;60:507-511. doi: 10.1161/HYPERTENSIONAHA.112.194845.
52. George EM, Palei AC, Granger JP. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertens. 2012;21:157-162. doi: 10.1097/MNH.0b013e328350094b.
53. LaMarca B, Cornelius D, Wallace K. Elucidating immune mechanisms causing hypertension during pregnancy. Physiology (Bethesda). 2013;28:225-233. doi: 10.1152/physiol.00006.2013.